Skip to content

Can Alternate Day Fasting Help Reverse Liver Disease? Insights from the FAST Trial

Effect of alternate day fasting over standard medical management alone to reverse non-alcoholic steatohepatitis, A randomized controlled trial. FAST trial - FAST Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069119
Enrollment
90
Registered
2024-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Alternate day fasting with SMT: Fasting protocol in the intervention arm. Intervention2: Standard medical management: SMT only. Intervention3: Alternate day fasting with SMT in the inte

Sponsors

Intitute of Liver and BIliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: NASH patients, Age 18-65 years. BMI 25-40kg/m3, and CAP more than 290. Stable weight in the last 3 months prior to enrolling in the study(less than 5kg weight variation). Imaging showed steatotic liver disease, liver stiffness less than 14kPa measured by fibroscan. Histologically proven NASH/MASH, fibrosis up to F3. Subjects willing to participate in the study

Exclusion criteria

Exclusion criteria: Liver stiffness more than 14kPa measured by fibroscan or Fibrosis more than F3. Diabetes with HbA1c more than 8.5%. Patients with another co-existing active liver disease e.g. hepatitis B or C, alcoholic liver disease. Patients with cirrhosis, HCC, or other malignancy. Chronic kidney disease, cardiovascular disorders, uncontrolled hypertension. Chronic infections, chronic inflammatory diseases. Patients on weight loss medications e.g semaglutide. Pregnant or lactating women and those planning a pregnancy. A patient who is not willing to participate in the study, or failed to provide the consent

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is a reversal of NASH over a 24-week duration.Timepoint: 24weeks

Secondary

MeasureTime frame
a. Improvement in the quality of life index b. Reversal of stage of fibrosis c. No progression of fibrosis d. Reversal of fat content e. Quality of life: cardiorespiratory performance f. Anthropometry g. Improvement in glycaemic status h. Decreased liver fat content as measured by fibroscan i. Change in bone mineral density as measured by DEXA scan j. Change in faecal microbiota.Timepoint: 1, 3 6 months

Countries

India

Contacts

Public ContactBabu Lal Meena

Institite of Liver and Biliary Sciences

drbabupgi@gmail.com9781100898

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026